For example, in a Phase 1/2 clinical trial (NCT00204607), subcutaneous injection of protamine-stabilized mRNAs encoding Melan-A, Tyrosinase, gp100, Mage-A1, Mage-A3, and survivin in 21 patients with metastatic melanoma demonstrated that the vaccine was safe with no grade II adverse events and activated the immune response. Here, PMEL is linked to metastatic melanoma.